Loading asset research
Cue Biopharma Inc. Common Stock
CUENasdaq · USD · StocksQuote as of · Exchange session not verified$28.74
+2.64%
Today
CUE
Loading 1D prices…
Market cap
$208.8M
Volume
122.8K
52w high
$45.5052w low
$4.98Company profile
Cue Biopharma Inc. Common Stock
Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases. It also developed the Immuno-STAT platform, which targets disease-specific T cells in vivo without broad immune modulation. The company's lead autoimmune candidate is CUE-401, a bifunctional IL-2 and TGF-B program that is advancing towards Phase 1 development to regulate inflammation and drive Treg-mediated tolerance. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
Boston, MA, United States
Employees
29
Fiscal year end
1231
CIK
1645460
Session & valuation
Open$28.38
Previous close$28.00
Day high$28.89
Day low$27.50
30-day avg. volume188.3K
Outstanding shares7.3M
Diluted EPS-$0.28
Latest annual period
P/E (trailing)-102.64
P/E (forward)-59.88
Price / book65.02
Beta2.46
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2834
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| NKTXNkarta Inc. Common Stock | $208.4M | $0.00 | — | -$1.41 | +3.56% | Buy |
| MSLESatellos Bioscience Inc. Common Stock | $206.9M | $0.00 | — | -$1.70 | +1.49% | Buy |
| PEPGPepGen Inc. Common Stock | $206.1M | $0.00 | — | -$2.12 | -1.16% | Buy |
| ANTXAN2 Therapeutics Inc. Common Stock | $204.2M | $0.00 | — | -$1.16 | -4.92% | Buy |
| DERMJourney Medical Corporation Common Stock | $204.1M | $61.2M | -18.67% | -$0.47 | +2.12% | Buy |